Qyuns Therapeutics
Taizhou
About Qyuns Therapeutics
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $189.0M
- Funding stage: IPO
- Last round: Series C (Mar 2022)
- Ticker: hkg:2509
- Website: qyuns.net
- Phone: +86 0523-80276311
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/qyuns-therapeutics-4514 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.